Problem 1: What made the difference between the two analytical perspectives: societal vs. third-party payer?
Problem 2: What was the minimum value of the monthly cost of sildenafil be ($?), which made the sildenafil treatment no longer cost-effective compared to no treatment at the willingness-to-pay threshold of $50,000 per QALY? If you decide there was no applicable minimum value, enter 999,999.999.
Here the article:
Chapter: Annals of Internal Medicine By Kenneth J. Smith and Mark S. Roberts